|
|
|
Volumn 61, Issue 4, 2006, Pages
|
|
What will it take to reap the clinical benefits of pharmacogenomics?
a,b,c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
FLUOROURACIL;
IRINOTECAN;
MERCAPTOPURINE;
METHOTREXATE;
TIOGUANINE;
TRASTUZUMAB;
WARFARIN;
BREAST CANCER;
COMMERCIAL PHENOMENA;
CONSENSUS DEVELOPMENT;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG LABELING;
DRUG LEGISLATION;
DRUG SAFETY;
ECONOMIC ASPECT;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HUMAN;
INFORMED CONSENT;
LEGAL ASPECT;
MALPRACTICE;
MEDICAID;
MEDICAL PRACTICE;
MEDICARE;
OFF LABEL DRUG USE;
PHARMACOGENOMICS;
REIMBURSEMENT;
REVIEW;
RISK BENEFIT ANALYSIS;
UNITED STATES;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG DESIGN;
DRUG LABELING;
DRUG THERAPY;
GENETIC SCREENING;
HUMANS;
LEGISLATION, DRUG;
PHARMACOGENETICS;
UNITED STATES;
|
|
EID: 33845579830
PISSN: 1064590X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (22)
|
|
References (0)
|
